CSV May 16, 2022 through May 16, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEVALBUTER	ADDITIONAL R	*USP37–NF32*	3513	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OL HYDROCHLORIDE	EQUIREMENTS/*USP Reference Standards <11>*						*Supplement to USP38–NF33*	Levalbuterol Related Compound H RS: Change 4-[2-(*tert*-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol. $C_{14}H_{23}NO_3$ 253.34 to: 4-[2-(*tert*-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol acetate. $C_{14}H_{23}NO_3 \cdot C_2H_4O_2$ 313.39
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION	ASSAY/*Procedure*	*USP39–NF34*	3529	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *System suitability solution*:Change USP Diphenhydramine Hydrochloride Related Compound A RS to: USP Diphenhyd

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ramine Related Compound A RS AND Line 4 of *System suitability*: Change for diphenhydramine hydrochloride related compound A and diphenhydramine hydrochloride are to: for diphenhydramine related compound A and diphenhydramine are
LEVODOPA	IMPURITIES	*USP37–NF32*	3533	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Row 6 of Column 1 of *Table 1*: Change 1-Veratrylglycine to: L-

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Veratrylglycine[a] AND Add a footnote: [a] 3-(3,4-Dimethoxyphenyl)-L-alanine.
FELBAMATE TABLETS	IM PURITIES/*Organic Impurities/System suitability/Suitability requirements*	*USP36–NF31*	3537	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Resolution*: Change NMT 2 to: NLT 2
LEVOTHYROXINE SODIUM TABLETS	IM PURITIES/*Organic Impurities/Procedure: Limit of Liothyronine Sodium*	*USP37–NF32*	3548	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Acceptance criteria*: Change NMT 2.0% of liothyronine to: NMT 2.0% of liothyronine sodium
PIPERAZINE PHOSPHATE	*Assay*	*USP42–NF37*	3549	31-May-2019	1-Jun-2019	*NA*	*NA*	Change Each mL of 0.1 N perchloric acid is equivalent to 7.953 mg of C

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_4H_{10}N_2 \cdot 2HCl$. to: Each mL of 0.1 N perchloric acid is equivalent to 9.207 mg of $C_4H_{10}N_2 \cdot H_3PO_4$.
FENTANYL	IM PUR ITIES/*Organic Impuri ties/Acceptance criteria*	*USP36–NF31*	3554	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Footnote f of Table 2: Change *N* -Phenyl -*N* -[1-(2-phenyleth yl)-4-piperidinyl] acetanilide hydrochloride, or acetyl fentanyl. to: *N* -(1-Phenethylpi per idin-4- yl)-*N* -phenylacetami de.
CONSTRUCT HUMAN	SPECIFIC TESTS/	*USP40–NF35*	3561	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 2 of *L-Glutamine*

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FIBROBLASTS IN BILAYER SYNTHETIC SCAFFOLD	*Metabolic Activity Assessment*							*solution*: Change 29.2 g to: 2.92 g
LINDANE CREAM	ASSAY/ *Procedure/ Chromatographic system/ Temperatures*	*USP37–NF32*	3561	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	After the *Injection port* subsection: Add a new subsection *Detector*: 250°
DOBUTAMINE INJECTION	IDENTIFICATION/*A.*	*USP39–NF34*	3561	31-Mar-2017	1-Apr-2017	*USP41–NF36*	*USP41–NF36*	Line 1 of *Sample solution*: Change 10 mg/mL of dobutamine hydrochloride in methanol, clarified by centrifugation to: Use the neat Injection.
RACEPINEPHRINE	*USP Reference standards <11>*	*USP41–NF36*	3564	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Add USP Epinephrine Bitartrate RS
RACEPINEPHRINE	ADDITIONAL REQUIREMENT	*USP41–NF36*	3564	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to*	Add *USP Reference*

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INHALATION SOLUTION	S						*USP41–NF36*	*Standards <11>* USP Epinephrine Bitartrate RS
RACEPINEPHRINE HYDROCHLORIDE	*USP Reference standards <11>*	*USP41–NF36*	3565	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Add USP Epinephrine Bitartrate RS
POLYVINYL ALCOHOL	IDENTIFICATION	*USP42–NF37*	3566	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *B*: Change It meets the requirements in the test *Viscosity—Capillary Methods <911>*, *Viscosity—Rotational Methods <912>*, and *Viscosity—Rolling Ball Method <913>*. to: It meets the requirements in the test *Viscosity—Capillary Methods <911>*, *Viscosity—Rotational Methods <912>*, or

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Viscosity—Rolling Ball Method <913>.
FERUMOXSIL ORAL SUSPENSION	*Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912>*	*USP36–NF31*	3572	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1: Change and to: or
FEXOFENADINE HYDROCHLORIDE TABLETS	ASSAY/ *Procedure*	*USP36–NF31*	3576	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 6 of *Sample stock solution*: Change (equivalent to 80% of the total flask volume) to: (sufficient to fill the flask to 80% of its volume)
POLYVINYL ALCOHOL	IDENTIFICATION/*A.*	*USP43–NF38*	3593	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Infrared Absorption* <197K> to: *Spectroscopic Identification Tests* <197>, *Infrared Spectroscopy*: 197K

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUOCINONIDE TOPICAL SOLUTION	*Alcohol content*	*USP36–NF31*	3618	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Standard solution*: Change Dilute 20.0 mL of USP Alcohol to: Dilute 20.0 mL of alcohol
FLUPHENAZINE DECANOATE INJECTION	*Assay*	*USP36–NF31*	3639	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 11 of *Standard preparation*: Delete (1:5) AND Line 8 of *Assay preparation*: Delete (1:5)
PRAVASTATIN SODIUM	ADDITIONAL REQUIREMENTS	*USP43–NF38*	3645	29-May-2020	1-Jun-2020	*NA*	*NA*	In *USP Reference Standards <11>/USP Pravastatin Related Compound A RS*: Change 446.51 to: 446.52
GALANTAMINE	IM	*USP38–NF33*	3646	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second*	Line 8 of

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROBROMIDE	PURITIES/*Organic Impurities*						*Supplement to USP39–NF34*	*Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times (100/100 ? L)$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times (100/[100 ? L])$
GALANTAMINE TABLETS	PERFORMANCE TESTS/ *Dissolution*	*USP38–NF33*	3649	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 6 of *Analysis* in *Test 1*: Change Result = $(A_U/A_S) \times (C_S/L) \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(A_U/A_S) \times (C_S/L) \times (M_{r1}/M_{r2}) \times V \times 100$ AND Add to the variable definition list in *Test 1* V = volume of *Medium*, 500 mL AND

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Equation in *Test 3*: Change Result = $(r_U/r_S) \times (C_S/L) \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(r_U/r_S) \times (C_S/L) \times (M_{r1}/M_{r2}) \times V \times 100$ AND Add to the variable definition list in *Test 3* V = volume of *Medium*, 500 mL
PRAZIQUANTEL TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	3650	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *For products for veterinary use/Apparatus 2*: Change peak vessels to: apex vessels
MANNITOL INJECTION	*Assay*	*USP37–NF32*	3653	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Change: *Mobile phase*, *Resolution solution*, and *Chromatographic*

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								system—Proceed as directed in the *Assay* under *Mannitol*. to: *Mobile phase*—Use degassed water. *Resolution solution*—Dissolve sorbitol and USP Mannitol RS in water to obtain a solution having concentrations of about 4.8 mg per mL of each. *Chromatographic system* (see *Chromatography <621>*)—The liquid chromatograph is equipped with a refractive index detector that is

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								maintained at a constant temperature and a 4-mm × 25-cm column that contains packing L19. The column temperature is maintained at a temperature between 30° and 85° controlled within ±2° of the selected temperature, and the flow rate is about 0.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the relative standard deviation for replicate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								injections is not more than 2.0%. In a similar manner, chromatograph the *Resolution solution*: the resolution, *R*, between the sorbitol and mannitol peaks is not less than 2.0. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under Mannitol. to: Separately inject equal volumes (about 20 µL) of the *Assay preparation* and the *Standard preparation* into

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the chromatograph, record the chromatograms, and measure the responses for the major peaks.
MAPROTILINE HYDROCHLORIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP37–NF32*	3655	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 3 of *Analysis*: Change Determine the labeled amount of maprotiline hydrochloride to: Determine the percentage of the labeled amount of maprotiline hydrochloride
EFAVIRENZ	IMPURITIES/*Organic Impurities*	*USP39–NF34*	3656	27-Jan-2017	1-Feb-2017	*USP41–NF36*	*Second Supplement to USP40–NF35*	Row 4 of Column 1 of *Procedure 1*/*Impurity Table 1*:Change Efavirenz pent-3-ene-1-yne (*cis*)[c] to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Efavirenz pent-3-ene-1-yne (*trans*)[c] AND Row 5 of Column 1 of *Procedure 1*/*Impurity Table 1*:Change Efavirenz pent-3-ene-1-yne (*trans*)[d] to: Efavirenz pent-3-ene-1-yne (*cis*)[d] AND Row 3 of Column 1 of *Procedure 2*/*Impurity Table 2*: Change Efavirenz pent-3-ene-1-yne (*cis*)[a] to: Efavirenz pent-3-ene-1-yne (*trans*)[a] AND

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Row 4 of Column 1 of *Procedure 2*/*Impurity Table 2*:Change Efavirenz pent-3-ene-1-yne (*trans*)[b] to: Efavirenz pent-3-ene-1-yne (*cis*)[b]
LEVETIRACETAM	ADDITIONAL REQUIREMENTS	*USP35–NF30*	3659	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 9 of *USP Reference Standards* <*11*>: Change $C_8H_{14}ClNO_3$ 207.65 to: $C_8H_{15}ClN_2O_2$ 206.67
RIZATRIPTAN BENZOATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	3662	26-Oct-2018	1-Nov-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 6 of USP Rizatriptan Benzoate System Suitability Mixture RS: Change 269.34) to: 269.35)

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOSPHENYTOIN SODIUM	*USP Reference standards <11>*	*USP36–NF31*	3679	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 6: Change $C_{14}H_{15}NO_2$ to: $C_{14}H_{13}NO_2$
FOSPHENYTOIN SODIUM INJECTION	*USP Reference standards <11>*	*USP36–NF31*	3680	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 6: Change $C_{14}H_{15}NO_2$ to: $C_{14}H_{13}NO_2$
FOSPHENYTOIN SODIUM INJECTION	*Assay*	*USP36–NF31*	3680	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Assay preparation*: Change Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin, to: Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin sodium,
DEXCHLORPHENIRAMINE	ADDITIONAL REQUIREMENT	*USP40–NF35*	3685	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to*	Line 2 of USP Chlorpheniramine

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MALEATE	S/*USP Reference Standards <11>*						*USP41–NF36*	Related Compound C RS: Change 3-(4-Chlorophenyl-*N*-methyl-3-(pyridin-2-yl)propan-1-amine. $C_{15}H_{17}ClN_2$ 260.76 to: 3-(4-Chlorophenyl)-*N*-methyl-3-(pyridin-2-yl)propan-1-amine maleate. $C_{15}H_{17}ClN_2 \cdot C_4H_4O_4$ 376.83
GADOTERIDOL INJECTION	*Bacterial endotoxins <85>*	*USP36–NF31*	3701	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2: Change gadoteridol. to: Gadoteridol Injection.
ENTECAVIR	ASSAY/ *Procedure*	*USP39–NF34*	3704	27-Jan-2017	1-Feb-2017	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 5 of *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ to: Result = (*r*

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U/r_S$) × (C_S/C_U) × 100 AND Line 14 of *Analysis*: Delete M_{r1}=molecular weight of anhydrous entecavir, 277.28 M_{r2}=molecular weight of entecavir, 295.29
LORATADINE ORALLY-DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards*	*USP35–NF30*	3714	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 4 of *USP Reference Standards*: Change 8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridine. to: 8-Chloro-5,6-dihydro-11-(piperidi

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								H -benzo[5,6]cyclohe pta[1,2-*b*]pyridine. AND Line 6: Change 310.83 to: 310.82 AND Line 8: Change 8-Chloro-6,11-dihydro -11-(*N* -methyl-4-piperidylid ene)-5*H* -benzo[5,6]cyclohe pta[1,2-*b*]pyridine. to: 8-Chloro-5,6-dihydro-1 1-(*N* -methylpiperidin -4

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-ylid ene)-11*H* -benzo[5,6]cycl ohe pta[1,2-*b*]pyridine. AND Line 10: Change 324.88 to: 324.85
METFORMIN H YDROCHLORI DE EXTENDED-RELEASE TABLETS	PERFORMANC E TESTS/ *Dissolution <711>*	*USP37–NF32*	3732	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Equation in *Test 1*: Change Result = $[(A_U/A_S) \times C_S \times (V ? V_S) + (C_{60} \times V_S) + (C_{180} \times V_S) \times 100]/L$ to: Result = $[(A_U/A_S) \times C_S \times (V ? V_S) + (C_{60} \times V_S) + (C_{180} \times V_S)] \times (100/L)$ AND Equation 3 in *Test 2*: Change Result = $[C_2 \times (V ? SV_1) + C_1 \times SV$

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_1$×100]/*L* to: Result = [C_2 × (*V* ? SV_1) + C_1 ×SV_1] ×(100/*L*) AND Equation 4 in *Test 2*: Change Result = {C_n ×[*V* ? (*n* ? 1)V_S] + (C_1 + C_2 + ... + C_{n-1}) × V_S ×100}/*L* to: Result = {C_n ×[*V* ? (*n* ? 1)V_S] + (C_1 + C_2 + ... + C_{n-1}) × V_S} ×(100/*L*)
PROPOFOL	IM PURITIES/*Organic Impurities, Procedure 2*	*USP43–NF38*	3739	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Table 3*: Delete Propofol related compound B[b] 0.8 1.0 0.05 AND Change Propofol related compound A[c] to: Propofol related compound A[b]

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Change [b] 2,6-Diisopropylbenzoquinone. [c] 3,3?-5,5?-Tetraisopropyldiphenol. to: [b] 3,3?-5,5?-Tetraisopropyldiphenol.
GLUCONOLACTONE	IDENTIFICATION/*A.*	*USP36–NF31*	3742	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 5 of *Analysis*: Change crystals of the phenylhydrazine of gluconic acid to: crystals of the phenylhydrazide of gluconic acid
METHADONE HYDROCHLORIDE ORAL SOLUTION	OTHER COMPONENTS	*USP37–NF32*	3744	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 3 of *Alcohol Determination*: Change gas–liquid chromatographic

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								procedure to: gas chromatographic procedure
PROPRANOLOL HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	3746	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability*/*Suitability requirements*/*Relative standard deviation*: Change NMT 5.0, to: NMT 5.0%,
POWDERED DIGITALIS	IDENTIFICATION/*B. Thin-Layer Chromatographic Identification Test*	*USP40–NF35*	3762	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *Standard solution A*: Change lead acetate, to: lead acetate TS, AND Line 11 of *Analysis*: Change Locate the two prominent

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								bands from *Standard solution A* corresponding in R_F value to the two bands from *Standard solution B*. to: Locate the prominent bands from *Standard solution A* corresponding in R_F value to the band from *Standard solution B*.
METHOTREXATE	IMPURITIES/*Organic Impurities/Procedure 1: Related Compounds*	*USP37–NF32*	3762	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Standard solution A*: Change 0.1 ?g/mL of USP Methotrexate RS in *Solution A*, from the *Standard stock solution* to:

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								0.1 µg/mL of USP Methotrexate RS in *Solution A*, from *Standard stock solution A*
HYDROCHLORIC ACID INJECTION	ASSAY/ *Procedure*	*USP38–NF33*	3770	29-Jan-2016	1-Feb-2016	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 8 of *Analysis*: Change *F* = equivalency factor, 18.23 mg/mEq to: *F* = equivalency factor, 36.46 mg/mEq
GRANISETRON HYDROCHLORIDE INJECTION	*Assay*	*USP36–NF31*	3772	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 10 of *Procedure*: Change $100(312.41 / 348.87)(C/L)(r_U / r_S)$ to: $100(312.41 / 348.87)(C/C_U)(r_U / r_S)$ AND Line of 14 of *Procedure*:

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change *L* is as defined above; to: C_U is the nominal concentration, in mg per mL, of granisetron in the *Assay preparation*;
QUAZEPAM	ADDITIONAL REQUIREMENTS/*USP Reference standards <11>*	*USP43–NF38*	3790	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Quazepam Related Compound A RS: Change 7-Chloro-1-(2,2,2 trifluoroethyl)-5-(2-Fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one. to: 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2*H*-1,4-benzodiazepine-2-one.
QUAZEPAM	ADDITIONAL R	*USP43–NF38*	3791	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	EQUIREMENTS/*USP Reference standards <11>*							Quazepam Related Compound A RS: Change 7-Chloro-1-(2,2,2 trifluoroethyl)-5-(2-Fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one. to: 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2*H*-1,4-benzodiazepine-2-one.
HYDROXYZINE PAMOATE ORAL SUSPENSION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	3817	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Delete USP Hydroxyzine Hydrochloride RS
METFORMIN HYDROCHLORIDE TABLETS	*Dissolution* <711>/*Test 3*	*USP35–NF30*	3830	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Lines 6 and 7 of *Procedure*: Change $r_U \times C_S \times 900 \times 100/r_S \times D \times LC$ to: $r_U \times C_S \times 1000 \times 100/r$

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$s \times D \times LC$ AND Line 11 of *Procedure*: Change 900 is the volume to: 1000 is the volume
MICONAZOLE INJECTION	IDENTIFICATION/*A./ Chromatographic system*	*USP37–NF32*	3831	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Spray reagent*: Change (Dragendorff's reagent) to: (Dragendorff's TS)
RALTEGRAVIR TABLETS	DEFINITION	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	Change ($C_{20}H_{20}FN_6O_5$) to: ($C_{20}H_{21}FN_6O_5$)

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 19
- Page 20